This has been achieved by measuring circulating tumor DNA (ctDNA) [13, 14] in patient blood either by detection of genetic changes such as single nucleotide polymorphism (SNP) patterns or somatic gene mutations as in the recent example of the TERT C228T promoter mutation [15], or by identifying tumor associated DNA methylation patterns in cell free DNA (cfDNA) [16]. Here, TERT is linked to neoplasm.